Department of Public Health and Clinical Medicine, Section of Medicine, Umeå University Hospital, B41, 90185, Umeå, Sweden.
BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, UK.
Respir Res. 2020 Jun 26;21(1):162. doi: 10.1186/s12931-020-01430-z.
Ischemic heart disease is common in COPD and associated with worse prognosis. This study aimed to investigate the presence and prognostic impact of biomarkers of myocardial injury and ischemia among individuals with COPD and normal lung function, respectively.
In 2002-04, all individuals with airway obstruction (FEV/VC < 0.70, n = 993) were identified from population-based cohorts, together with age and sex-matched non-obstructive referents. At re-examination in 2005, spirometry, Minnesota-coded ECG and analyses of high-sensitivity cardiac troponin I (hs-cTnI) were performed in individuals with COPD (n = 601) and those with normal lung function (n = 755). Deaths were recorded until December 31st, 2010.
Hs-cTnI concentrations were above the risk stratification threshold of ≥5 ng/L in 31.1 and 24.9% of those with COPD and normal lung function, respectively. Ischemic ECG abnormalities were present in 14.8 and 13.4%, while 7.7 and 6.6% had both elevated hs-cTnI concentrations and ischemic ECG abnormalities. The 5-year cumulative mortality was higher in those with COPD than those with normal lung function (13.6% vs. 7.7%, p < 0.001). Among individuals with COPD, elevated hs-cTnI both independently and in combination with ischemic ECG abnormalities were associated with an increased risk for death (adjusted hazard ratio [HR]; 95% confidence interval [CI] 2.72; 1.46-5.07 and 4.54; 2.25-9.13, respectively). Similar associations were observed also among individuals with COPD without reported ischemic heart disease.
In this study, elevated hs-cTnI concentrations in combination with myocardial ischemia on the electrocardiogram were associated with a more than four-fold increased risk for death in a population-based COPD-cohort, independent of disease severity.
缺血性心脏病在 COPD 中很常见,与预后更差有关。本研究旨在分别研究 COPD 患者和肺功能正常者中心肌损伤和缺血的生物标志物的存在及其对预后的影响。
2002-04 年,从基于人群的队列中确定所有气道阻塞(FEV/VC<0.70,n=993)的个体,以及年龄和性别匹配的非阻塞性对照者。在 2005 年的复查中,对 COPD(n=601)和肺功能正常者(n=755)进行肺功能检查、明尼苏达编码心电图和高敏心肌肌钙蛋白 I(hs-cTnI)分析。记录截至 2010 年 12 月 31 日的死亡情况。
hs-cTnI 浓度高于风险分层阈值(≥5ng/L)的患者分别占 COPD 和肺功能正常患者的 31.1%和 24.9%。心电图有缺血性改变的分别占 14.8%和 13.4%,同时 hs-cTnI 浓度升高和心电图有缺血性改变的分别占 7.7%和 6.6%。COPD 患者的 5 年累积死亡率高于肺功能正常患者(13.6% vs. 7.7%,p<0.001)。在 COPD 患者中,hs-cTnI 升高,无论是独立存在还是与心电图缺血性改变同时存在,均与死亡风险增加相关(校正后的风险比[HR];95%置信区间[CI]分别为 2.72;1.46-5.07 和 4.54;2.25-9.13)。在没有报告缺血性心脏病的 COPD 患者中也观察到了类似的相关性。
在这项基于人群的 COPD 队列研究中,hs-cTnI 浓度升高与心电图上的心肌缺血相结合,与死亡风险增加超过四倍相关,与疾病严重程度无关。